X0306 4 2022-04-30 0 0001404644 Neoleukin Therapeutics, Inc. NLTX 0001859997 Patel Priti C/O NEOLEUKIN THERAPEUTICS, INC. 188 EAST BLAINE STREET, #450 SEATTLE WA 98102 0 1 0 0 Chief Medical Officer Common Stock 2022-04-30 4 M 0 10000 0.00 A 12000 D Common Stock 2022-05-02 4 S 0 5538 1.2186 D 6462 D Restricted Stock Units 0.00 2022-04-30 4 M 0 10000 0.00 A Common Stock 10000 10000 D Includes 2,000 shares of common stock acquired by the Reporting Person on November 15, 2021 pursuant to the Issuer's employee stock purchase plan. The sales reported on this Form 4 represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"). These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. Represents the weighted average sale price. The lowest price at which shares were sold was $1.21 and the highest price at which shares were sold was $1.25. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the ranges set forth herein. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration. The RSUs will vest as to 1/2 of the total number of shares underlying the award on each of April 30, 2022 and April 30, 2023, subject to the Reporting Person's provision of service to the Issuer on each vesting date. The RSUs do not expire; these securities either vest and settle or are canceled prior to the vesting date. /s/ Sean Smith, as Attorney-in-Fact for Priti Patel 2022-05-03